CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $489,048 | -15.4% | 32,800 | -37.9% | 0.02% | -17.2% |
| Q2 2023 | $578,160 | +25.6% | 52,800 | 0.0% | 0.03% | +16.0% |
| Q1 2023 | $460,416 | +39.1% | 52,800 | 0.0% | 0.02% | +25.0% |
| Q4 2022 | $331,056 | +78.9% | 52,800 | 0.0% | 0.02% | +66.7% |
| Q3 2022 | $185,000 | +18.6% | 52,800 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $156,000 | -4.9% | 52,800 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $164,000 | -28.7% | 52,800 | 0.0% | 0.01% | -38.5% |
| Q2 2021 | $230,000 | -3.8% | 52,800 | 0.0% | 0.01% | -13.3% |
| Q1 2021 | $239,000 | -21.1% | 52,800 | 0.0% | 0.02% | -28.6% |
| Q4 2020 | $303,000 | -33.0% | 52,800 | -15.5% | 0.02% | -40.0% |
| Q3 2020 | $452,000 | +172.3% | 62,500 | +31.6% | 0.04% | +150.0% |
| Q2 2020 | $166,000 | – | 47,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |